BTIG Research reaffirmed their buy rating on shares of AtriCure (NASDAQ:ATRC) in a research report sent to investors on Tuesday, AnalystRatings.com reports. BTIG Research currently has a $35.00 price target on the medical device company’s stock.

Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of AtriCure from a buy rating to a hold rating in a report on Tuesday, July 23rd. BidaskClub upgraded shares of AtriCure from a buy rating to a strong-buy rating in a research report on Friday, July 26th. ValuEngine downgraded shares of AtriCure from a strong-buy rating to a buy rating in a research report on Wednesday, June 19th. Finally, Northland Securities downgraded shares of AtriCure from an outperform rating to a market perform rating and set a $30.00 price target on the stock. in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $36.57.

Shares of ATRC stock opened at $26.94 on Tuesday. AtriCure has a 12-month low of $26.11 and a 12-month high of $36.49. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.10 and a current ratio of 3.72. The firm’s 50 day moving average is $31.03 and its 200 day moving average is $29.98.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. AtriCure had a negative net margin of 9.46% and a negative return on equity of 13.06%. The company had revenue of $58.90 million for the quarter, compared to analysts’ expectations of $57.76 million. During the same quarter last year, the company posted ($0.19) earnings per share. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. On average, analysts predict that AtriCure will post -0.9 earnings per share for the current year.

In other AtriCure news, CEO Michael H. Carrel sold 1,454 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $33.00, for a total value of $47,982.00. Following the transaction, the chief executive officer now directly owns 637,557 shares in the company, valued at $21,039,381. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael H. Carrel sold 25,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $32.00, for a total transaction of $800,000.00. Following the completion of the transaction, the chief executive officer now owns 661,103 shares in the company, valued at $21,155,296. The disclosure for this sale can be found here. Insiders sold 37,158 shares of company stock worth $1,169,102 over the last quarter. Insiders own 8.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in ATRC. Invesco Ltd. raised its position in shares of AtriCure by 4,185.4% during the 2nd quarter. Invesco Ltd. now owns 382,256 shares of the medical device company’s stock valued at $11,406,000 after purchasing an additional 373,336 shares during the period. Waddell & Reed Financial Inc. bought a new stake in shares of AtriCure during the 2nd quarter valued at $10,825,000. GW&K Investment Management LLC raised its position in shares of AtriCure by 73.2% during the 2nd quarter. GW&K Investment Management LLC now owns 843,747 shares of the medical device company’s stock valued at $25,177,000 after purchasing an additional 356,652 shares during the period. Nuveen Asset Management LLC raised its position in shares of AtriCure by 418.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 423,336 shares of the medical device company’s stock valued at $12,632,000 after purchasing an additional 341,689 shares during the period. Finally, Tamarack Advisers LP raised its position in shares of AtriCure by 58.8% during the 2nd quarter. Tamarack Advisers LP now owns 675,000 shares of the medical device company’s stock valued at $21,195,000 after purchasing an additional 250,000 shares during the period. Hedge funds and other institutional investors own 89.99% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Featured Article: Futures Contract

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.